ArticlePharmaceuticals (Basel, Switzerland)2021
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Targeted βJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Development of dual SSTRSC medicinal chemistry · 2026Article
- SSTR2 receptor states and cellular metabolism modulateEANM innovation · 2026Article
- Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications.Theranostics · 2026Article
- Monte Carlo-based subcellular comparison of electron energy deposition byEJNMMI physics · 2025Article
- "Precision on Two Wheels"─Structural Refinement ofJournal of medicinal chemistry · 2025Article
- Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.EJNMMI radiopharmacy and chemistry · 2025Article
- Dose-Dependent Cellular Phenotypic Change Induced byBiomedicines · 2025Article
- Cytotoxicity Comparison ofMolecules (Basel, Switzerland) · 2025Article
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.Theranostics · 2025Article
- Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.EJNMMI research · 2024Article
- Current clinical application of lutetium‑177 in solid tumors (Review).Experimental and therapeutic medicine · 2024Review
- Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.Frontiers in nuclear medicine · 2024Article
- The heterobivalent (SSTR2/albumin) radioligand [Theranostics · 2024Article
- Comparative Saturation Binding Analysis ofACS omega · 2023Article
- Development of thePharmaceutics · 2023Article
- Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.Cancers · 2022Review
- Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.